Is NBS a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

2,754 people get NBS articles and Market Currents by email alert.

Get email alerts on NBS »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

NeoStem: Built For Success In Regenerative Medicine
Stone Fox Capital • Mon, Jun 3 • 8 Comments
NeoStem: A Biotech With Lots Of Promise
Equity Options Guru • Tue, May 28 • 5 Comments
NeoStem: A Simple Look At Regenerative Medicine
William Sterling • Thu, Apr 25 • 5 Comments
An Industry Outlook With Analyst Vernon Bernardino
Brian Nichols • Mon, Apr 22 • 5 Comments
The Vatican / NeoStem Partnership Looks To Create Interest And Advance Cell Therapy
Brian Nichols • Wed, Apr 10 • 28 Comments
Will AMR-001 Lead Neostem To The Promised Land?
EnhydrisPECorp • Mon, Apr 1 • 13 Comments
2012 Breakthroughs In Cell Therapy Development
Brian Nichols • Mon, Jan 7 • 46 Comments
With Osiris Overvalued, NeoStem Is A Better Buy
Amy Baldwin • Wed, Jan 2 • 14 Comments
NeoStem Awarded $1.2 Million Grant For VSEL Development
The Swiss Trader • Wed, Nov 21, 2012 • 15 Comments
Breaking Barriers In Cardiovascular Treatments
A John Hodge • Mon, Nov 19, 2012 • 2 Comments
NeoStem to Create Value with Billion Dollar Potential
Amy Baldwin • Wed, Nov 7, 2012 • 35 Comments
Neostem's Balancing Act A Boon For Shareholders
Ira Miller • Tue, Nov 6, 2012 • 15 Comments
NeoStem CEO Dr. Smith Talks PCT Potential And Explains Recent Bullish Developments
Brian Nichols • Mon, Nov 5, 2012 • 15 Comments
After A Data-Packed October, What Will November Bring For NeoStem?
The Swiss Trader • Thu, Nov 1, 2012 • 5 Comments
Possible Reverse Split Should Be The Catalyst Needed To Take NeoStem Shares Higher
Amy Baldwin • Tue, Oct 23, 2012 • 33 Comments
NeoStem: The Best Upside In An Innovating Space
Henry Kawabe • Sun, Oct 7, 2012 • 25 Comments
Watch For Short-Term Gains In Shares Of NeoStem
Brian Nichols • Wed, Oct 3, 2012 • 9 Comments
NeoStem: A Promising Investment Candidate In Stem Cell Treatment
The Swiss Trader • Mon, Sep 17, 2012 • 9 Comments
Developments Over The Next Year That Could Change NeoStem
A John Hodge • Wed, Sep 5, 2012 • 2 Comments
NeoStem's Promising VSEL Developments Are Good Signs For The Future Of Cell Therapy
The Swiss Trader • Thu, Jul 26, 2012 • 7 Comments

To learn more about Seeking Alpha Pro, click here.

A Focus On Stem-Cell Therapy And Regenerative Medicine For 2013
A John Hodge • Mon, May 20 • 4 Comments
3 Biotech Stocks With Potential
Equity Options Guru • Tue, May 14 • 10 Comments
5 Stocks To Watch For Gains Next Week
Brian Nichols • Sat, May 11 • 24 Comments
Interviewing Dr. Losordo: The Promising Development Of CD34 Cells
Brian Nichols • Wed, May 8 • 13 Comments
Stem Cells: Invest At Your Own Peril
EnhydrisPECorp • Wed, May 1 • 35 Comments
Regenerative Medicine's Time Has Come
Stock Investor • Sun, Apr 28 • 13 Comments
Stem Cells: Dreamers, Fools, And The Valley Of Death
EnhydrisPECorp • Thu, Apr 25 • 24 Comments
Investing In The Stem Cell Sector: An Overview
EnhydrisPECorp • Wed, Apr 17 • 25 Comments
5 Biotechnology Stocks That Greatly Outperformed The Market In Q1
Brian Nichols • Mon, Apr 15 • 2 Comments
5 Stocks To Watch Next Week For Gains
Brian Nichols • Sun, Apr 7 • 8 Comments
Biotechnology Super Panel Talks Development, Marketing And The Future
The Swiss Trader • Wed, Mar 27 • 8 Comments
Opexa: A Significant Growth Opportunity For Short-Term Traders And Long-Term Investors
Scott Matusow • Tue, Mar 26 • 29 Comments
The Future Of Medicine: A Look At 5 Stem Cell Companies
Craig Keolanui • Fri, Mar 22 • 4 Comments
Cell Therapy Leader Stephen Potter Talks Osiris, NeoStem And The Industry Itself
Brian Nichols • Tue, Mar 19 • 2 Comments
The Weekend Blitz: Finding Value, Market Behavior, & Diversification Related Plays
Brian Nichols • Mon, Mar 18 • 18 Comments
3 Biotech Stocks That Are Set-Up Nicely For Growth
A John Hodge • Sun, Mar 17 • 7 Comments
Seeking Opportunity: 10 Stocks To Watch Right Now
Brian Nichols • Fri, Mar 15 • 14 Comments
The Stem Cell Revolution Can Jump Start Your Portfolio: Jason Kolbert
Life Sciences Report • Fri, Mar 15 • 16 Comments
3 Undiscovered Biotech Companies For The Healthcare Investor
William Sterling • Mon, Mar 11 • 31 Comments
The Weekend Blitz: A Discussion Of Investment Strategies And Investment Ideas
Brian Nichols • Sun, Mar 10 • 16 Comments

There are no Transcripts on NBS.

NeoStem Announces Geographic Expansion of Intellectual Property Coverage of AMR-001 to Canada

GlobeNewswire (Mon, 8:52AM)
NeoStem's Subsidiary, PCT, Enters Into a Manufacturing Agreement With ImmunoCellular Therapeutics, Ltd. for Dendritic Cell Vaccines Targeting Brain and Other Cancers

GlobeNewswire (Jun 3, 2013)
NeoStem Announces Presentations at 2nd Baltic Stem Cell Meeting and Session to Feature VSEL(TM) Technology

GlobeNewswire (May 30, 2013)
NeoStem Announces Geographic Expansion of Intellectual Property Coverage of Cardiovascular Asset AMR-001

GlobeNewswire (May 16, 2013)
NeoStem to Present at Multiple Conferences in May

GlobeNewswire (May 14, 2013)
NeoStem's Subsidiary, Progenitor Cell Therapy, to Provide Autologous and Allogeneic Cellular Therapy Services to MedStar Georgetown University Hospital

GlobeNewswire (May 13, 2013)
NeoStem Clarification: No New Securities Being Issued

GlobeNewswire (May 9, 2013)
NeoStem CEO's Letter to Shareholders

GlobeNewswire (May 9, 2013)
NeoStem Announces Closing of Public Offering of Common Stock

GlobeNewswire (May 3, 2013)
NeoStem Announces Partial Exercise of Underwriters' Over-Allotment Option

GlobeNewswire (Apr 30, 2013)
NeoStem Announces Pricing of Public Offering of Common Stock

GlobeNewswire (Apr 29, 2013)
NeoStem Announces Proposed Public Offering of Common Stock

GlobeNewswire (Apr 29, 2013)
NeoStem's Subsidiary, Progenitor Cell Therapy, Enters Into a Services Agreement With Sentien Biotechnologies, Inc.

GlobeNewswire (Apr 29, 2013)
NeoStem to Present at Multiple Conferences in April

GlobeNewswire (Apr 1, 2013)
NeoStem Awarded Second Year of NIAID Research Grant for the Development of VSEL Technology for Radiation Exposure

GlobeNewswire (Mar 28, 2013)
NeoStem CEO's Letter to Shareholders

GlobeNewswire (Mar 19, 2013)
NeoStem's Subsidiary, Progenitor Cell Therapy, Launches Web-Based Service for Real-Time Cell Therapy Product Tracking

GlobeNewswire (Mar 18, 2013)
NeoStem Announces Intellectual Property Expansion in Cardiovascular Disease

GlobeNewswire (Mar 13, 2013)
NeoStem Announces 2012 Year End Financial Results and Business Update

GlobeNewswire (Mar 11, 2013)
NeoStem Reports Second Data Safety Monitoring Board Review: Continue With PreSERVE AMI Phase 2 Trial as Planned

GlobeNewswire (Mar 7, 2013)

NBS vs. ETF Alternatives

Company Description

NeoStem, Inc. engages in the development of proprietary cell therapy products. It is involved in the manufacture of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery, and consulting services. The... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Monday, June 3, 2:31 PM NeoStem (NBS -1%) says its subsidiary, Progenitor Cell Therapy, has entered a service agreement with ImmunoCellular Therapeutics (IMUC -0.2%) to provide cGMP manufacturing services to support R&D of IMUC's ICT-121 cell therapy product candidate, a dendritic cell vaccine targeting cells that express the glycoprotein CD133, which recent studies have shown to be possible markers for cancer. Comment! [Healthcare]
Thursday, May 16, 3:38 PM NeoStem (NBS +1.5%) holds in the green today after the company announced the geographic patent expansion of its lead product candidate, AMR-001, with the notice of a grant in Malaysia and notice of recommendation for allowance in the Philippines. These patents are in the family of US patent titled "Compositions and Methods of Vascular Injury Repair" and protected a chemotactic stem cell product enriched for CD34+ cells that treats injury from acute myocardial infarction. Comment! [Healthcare, Global & FX, On the Move]
Thursday, May 16, 10:46 AM Shares of stem cell research firms are rallying today on the back of an announcement today by the Oregon Health and Science University that they've successfully reproduced human stem cells by cloning. Cloning stem cells in this fashion could lead to cell therapies using a patient’s own cells and thereby avoid the problems of immune suppression: StemCells (STEM +2.2%), NeuralStem (CUR +2.1%), NeoStem (NBS +2.2%). Comment! [Healthcare, On the Move]
Thursday, May 16, 8:07 AM NeoStem (NBS) has its patent application for AMR-001 granted in Malaysia and appears close to a similar result in the Philippines. The company also says it has been granted a second patent in South Africa. AMR-001 (which will have 9 total patents after today's announcement) is the company's flagship product and NBS intends to complete enrollment in a Phase II trial this year. SA contributor Equity Options Guru is bullish based on what he believes are improving balance sheet dynamics. (PR) Comment! [Healthcare]
Thursday, May 9, 4:54 PM NeoStem (NBS): Q1 EPS of -$0.05 in-line. (PR) 5 Comments [Earnings, Breaking News, Healthcare]
Monday, April 29, 6:40 PM NeoStem (NBS) announces a public offering, saying it intends to use the proceeds for working capital, including research and development of cell therapeutic product candidates, including AMR-001, plus expansion of its business units, strategic transactions and other general corporate purposes. Terms and size of the offering have not yet been disclosed. Aegis Capital is acting as sole book-running manager. Shares -8% AH. 3 Comments [Healthcare, On the Move]
Wednesday, March 13, 9:32 AM NeoStem (NBS) unit Amorcyte receives a Notice of Allowance of claims from the U.S. Patent office for an application that covers a new way to treat damage to the heart muscle that's caused by a reduced blood supply and that utilizes a multi-dosing regimen. A major condition covered is the use of Amorcyte's AMR-001 for treating ischemia-induced congestive heart failure, which affects 5.8M people in the U.S. and 20M globally. (PR) Comment! [Healthcare]
Thursday, March 7, 8:11 AM NeoStem (NBS +3.8%) has received approval to continue the Phase II trial of its AMR-001 heart treatment following a second interim data and safety review by the Data Safety Monitoring Board. NeoStem is testing AMR-001 for the prevention of further major problems following heart attacks and hopes to complete enrollment in the study this year. (PR) Comment! [Healthcare, On the Move]
Wednesday, November 14, 2012, 9:01 AM NeoStem (NBS): Q3 EPS of -$0.06 misses by $0.01. Revenue of $4.4M beats by $0.9M. (PR) Comment! [Earnings, Healthcare]
Friday, August 24, 2012, 4:34 PM NeoStem (NBS) files a secondary offering to sell 22.97M shares of common stock for holders. Shares +3% AH. 4 Comments [Healthcare, On the Move]
Monday, June 18, 2012, 12:06 PM Neostem (NBS +1.6%) agrees to sell 51% of its interest in Suzhou Erye Pharmaceutical, a China-based generic pharmaceutical company, for $12.3M in cash. Included in the agreement is the the return to the company of 1.04M shares of common stock and the cancellation of 1.17M options and 640K common stock warrants, which collectively represent 1.3% of NBS' outstanding shares. Comment! [Global & FX, Healthcare, On the Move]

pagreen1966
Intend to purchase a shedful of $NBS shares today. The secondary offering has pushed the stock price down 22% in pre-market trading!
Apr 30, 9:11 AM
Reply (1)

• !Report Abuse
View all 1 replies
skywola: I try not to judge things based on pre-market trading, have made that mistake and learned from it. . . .
May 24, 11:12 AM
• !Report Abuse
Add a reply...

140 characters

Robbster
Biotech holds include $ARQL, $CUR, $GALE, $IMUC, $NBS, $PSTI, $ STEM, $NLNK. Questioning ARQL, NLNK, but holding for now...
Mar 12, 10:21 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

jsiebel720
$NBS: Anyone hear anything why the stock is trading the way it is. Called IR contact; Worthless & waste oftime. Any feedback is appreciated
Mar 5, 11:51 AM
Reply (5)

• !Report Abuse
View all 5 replies
jjwatts: bunch of pumpers all over the place is what i see, the company has potential so the pumpers are trying to take advantage of ppl
Mar 8, 6:30 AM
• !Report Abuse
uckinallstar: The stock bounced back yesterday, very volatile
Mar 8, 12:07 PM
• !Report Abuse
Add a reply...

140 characters

Robbster
So, for those following, my total development biotech portfolio as of today: $ARQL, $CUR, $DNDN, $GALE, $IMUC, $NBS, $NLNK, $PSTI, $STEM.
Jan 3, 8:24 PM
Reply (1)

• !Report Abuse
View all 1 replies
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
Jan 5, 3:09 PM
• !Report Abuse
Add a reply...

140 characters

Robbster
$NBS rationale' - 1) actual sales! 2) Two big pot. future revenue streams- growth as stem cell supplier to other bios, and ALS treatment.
Jan 3, 8:22 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Fincher
$NBS has been tanking for a while now, was nice run up since summer from 0,35-0,8.a bit of pause now and off we go into Q1 2013 rally again!
12/20/12
Reply (3)

• !Report Abuse
View all 3 replies
Fincher: a bit stronger word on mi side, fair play to you. just wanted to express a tad of frustration for a lack of upward momentum.
12/21/12
• !Report Abuse
gbstern13: Get used to it. Development stage biotech; long bouts of sideways drifting occasionally interrupted with sharp movement. Par for the course.
12/23/12
• !Report Abuse
Add a reply...

140 characters

chrismira12
$NBS Anyone know when a good time to buy in would be please?
12/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Weekly Stock Watch - $SIRI, $AEZS, $NBS, $VGLD - http://bit.ly/UD9PnC
10/9/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
$AMRN, $SSH, $NBS, $AEZS, $SIRI, $FCEL - Mid-Week Movers - http://bit.ly/QvWec9
10/4/12
Reply (1)

• !Report Abuse
View all 1 replies
wiesemc: Do you advise waiting until the AEZS split or purchase now?
10/4/12
• !Report Abuse
Add a reply...

140 characters

VFC's Stock House
$AMRN, $NBS, $AEZS, $ONTY, $SSH - Five share price dips that might just be temporary ... http://bit.ly/S1AJE7
9/27/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

jsiebel720
$NBS: Anyone hear anything why the stock is trading the way it is. Called IR contact; Worthless & waste oftime. Any feedback is appreciated
Mar 5, 11:51 AM
Reply (5)

• !Report Abuse
View all 5 replies
jjwatts: bunch of pumpers all over the place is what i see, the company has potential so the pumpers are trying to take advantage of ppl
Mar 8, 6:30 AM
• !Report Abuse
uckinallstar: The stock bounced back yesterday, very volatile
Mar 8, 12:07 PM
• !Report Abuse
Add a reply...

140 characters

Robbster
So, for those following, my total development biotech portfolio as of today: $ARQL, $CUR, $DNDN, $GALE, $IMUC, $NBS, $NLNK, $PSTI, $STEM.
Jan 3, 8:24 PM
Reply (1)

• !Report Abuse
View all 1 replies
Robbster: Tthese represent my "Dev. Biotech Fundamentals" strategy; breakthrough science, financials and leadership that support price appreciation.
Jan 5, 3:09 PM
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Complete Genomics (GNOM) and its DNA sequencing technology looks good. But Neostem (NBS) and stem cells...no. http://yhoo.it/KSyRFj
5/24/12
Reply (6)

• !Report Abuse
View all 6 replies
Maria Auziliadora: GNOM looks good and the other biotechs do too
5/25/12
• !Report Abuse
The Berenstain Bulls: @Maria: Yeah, I like GNOM as well, currently long a few shares.
Jan 2, 2:16 PM
• !Report Abuse
Add a reply...

140 characters

Fincher
$NBS has been tanking for a while now, was nice run up since summer from 0,35-0,8.a bit of pause now and off we go into Q1 2013 rally again!
12/20/12
Reply (3)

• !Report Abuse
View all 3 replies
Fincher: a bit stronger word on mi side, fair play to you. just wanted to express a tad of frustration for a lack of upward momentum.
12/21/12
• !Report Abuse
gbstern13: Get used to it. Development stage biotech; long bouts of sideways drifting occasionally interrupted with sharp movement. Par for the course.
12/23/12
• !Report Abuse
Add a reply...

140 characters

The Berenstain Bulls
Still long NBS, PSTI, NVLX. NVLX: http://on.mktw.net/MwvxpE
7/18/12
Reply (7)

• !Report Abuse
View all 7 replies
The Berenstain Bulls: @iadops40: Thank you, I will keep an eye on it.
10/24/12
• !Report Abuse
iadops40: lol, I sold that mid September, before the scandal
10/24/12
• !Report Abuse
Add a reply...

140 characters

VFC's Stock House
$AMRN, $SSH, $NBS, $AEZS, $SIRI, $FCEL - Mid-Week Movers - http://bit.ly/QvWec9
10/4/12
Reply (1)

• !Report Abuse
View all 1 replies
wiesemc: Do you advise waiting until the AEZS split or purchase now?
10/4/12
• !Report Abuse
Add a reply...

140 characters

iadops40
Huge all-star biotech conference (Rodman & Renshaw) in New York Sept. 9-11 CLSN GALE GERN IBIO INO KERX NVAX NBS ONTY VVUS
8/28/12
Reply (2)

• !Report Abuse
View all 2 replies
iadops40: http://bit.ly/RntWCr
8/28/12
• !Report Abuse
DAG1996: thanks for sharing that.
8/28/12
• !Report Abuse
Add a reply...

140 characters

iadops40
Huge all-star biotech conference (Rodman & Renshaw) in New York Sept. 9-11 CLSN GALE GERN IBIO INO KERX NVAX NBS ONTY VVUS
8/27/12
Reply (1)

• !Report Abuse
View all 1 replies
iadops40: http://bit.ly/RntWCr
8/27/12
• !Report Abuse
Add a reply...

140 characters

The Berenstain Bulls
PSTI, NBS, GNOM, and Nuvilex (NVLX) all looking swaggish as of late. http://bit.ly/P32kkI
8/9/12
Reply (1)

• !Report Abuse
View all 1 replies
The Berenstain Bulls: The Berenstain Bulls : "PSTI buy the dip." Wed, 10:55 AM http://bit.ly/LK9abW
8/9/12
• !Report Abuse
Add a reply...

140 characters

Husky Financial
NBS up 90% since i posted about it 3 months ago.. only person i know to have taken the advice was BernsteinBears congrat$ man
7/26/12
Reply (2)

• !Report Abuse
View all 2 replies
Ocean Man: I remember that - nice call Husky.
7/27/12
• !Report Abuse
Husky Financial: thanks OM hope all is well w/ you this summer
7/27/12
• !Report Abuse
Add a reply...

140 characters

The Berenstain Bulls
NBS moving up nicely, as it should. http://bit.ly/NtkaOj
6/11/12
Reply (1)

• !Report Abuse
View all 1 replies
The Berenstain Bulls: NBS, I like your style.
6/12/12
• !Report Abuse
Add a reply...

140 characters

benjikrigs
Does anyone else agree that its probably the same people who buy AAPL at 650 that naysay NBS at under 60 cents. I am long NBS.
6/11/12
Reply (2)

• !Report Abuse
View all 2 replies
weed: You're probably right.
6/11/12
• !Report Abuse
daniel_kol: I bet the people buying AAPL at $650 aren't even aware of NBS.
6/12/12
• !Report Abuse
Add a reply...

140 characters

Todd Theman
Lots of cash, no debt, several possible catalysts for NBS including possible sale of their Chinese subsidiary. Buying small position here.
4/27/12
Reply (1)

• !Report Abuse
View all 1 replies
Noreika: Added a position yesterday. #NBS
5/9/12
• !Report Abuse
Add a reply...

140 characters

NBS NeoStem, Inc

NBS

NeoStem, Inc